Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis.
Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -40.30 Increased by +97.26% | - |
| Nov 12, 24 | -111.07 Decreased by -131.39% | - |
| Aug 19, 24 | -4.19 Decreased by -355.29% | - |
| Apr 16, 24 | -36.82 Decreased by -2.71 K% | -29.81 Decreased by -23.52% |
| Feb 28, 24 | -1.47 K Decreased by -75.04 K% | -1.19 K Decreased by -23.52% |
| Nov 13, 23 | -48.00 Decreased by -810.82% | -7.98 Decreased by -501.50% |
| Aug 14, 23 | -0.92 Increased by +85.85% | -2.89 Increased by +68.17% |
| May 15, 23 | -1.31 Increased by +81.29% | -2.78 Increased by +52.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 3.17 K Decreased by -96.09% | -5.23 M Increased by +52.35% | Decreased by -164.62 K% Decreased by -1.12 K% |
| Sep 30, 24 | 6.85 K Decreased by -94.49% | -6.94 M Increased by +28.79% | Decreased by -101.26 K% Decreased by -1.19 K% |
| Jun 30, 24 | 44.28 K Decreased by -79.96% | -7.55 M Decreased by -32.87% | Decreased by -17.05 K% Decreased by -563.14% |
| Mar 31, 24 | 79.68 K Decreased by -63.52% | -14.73 M Decreased by -130.66% | Decreased by -18.49 K% Decreased by -532.26% |
| Dec 31, 23 | 81.30 K Decreased by -56.20% | -10.97 M Decreased by -34.03% | Decreased by -13.49 K% Decreased by -205.99% |
| Sep 30, 23 | 124.49 K Decreased by -61.47% | -9.75 M Decreased by -0.24% | Decreased by -7.83 K% Decreased by -160.18% |
| Jun 30, 23 | 220.98 K Increased by +2.92% | -5.68 M Increased by +2.87% | Decreased by -2.57 K% Increased by +5.62% |
| Mar 31, 23 | 218.41 K Increased by +3.87% | -6.39 M Decreased by -6.41% | Decreased by -2.92 K% Decreased by -2.45% |